NOVARTIS PHARMA AG
CIK 1030617 · last filed 2012-09-24
NOVARTIS PHARMA AG is a corporate insider who has filed 9 SEC Form 4 insider transactions across 2 companies since 2009. The most recent filing shows the insider sold $60.3M of ALNY on Sep 24, 2012. Across all open-market trades the lifetime net is −$58.6M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $911.9M across reported positions. The firm reports its address in Basel, V8. 33 SEC filings were submitted jointly with NOVARTIS AG.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ALNY price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
CH-4002
BASEL, V8
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ALNY | 10%+ Owner | 4,051,002 | $225.10 | $911.88M | -$60.28M | 1 | 2012-09-24 |
| IDENIX PHARMACEUTICALS INC (IDIX) Delisted | 10%+ Owner | 33,271,882 | — | — | $1.72M | 8 | 2012-02-23 |
Recent Filings
9 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2012-09-24 | ALNY | Sell (S) | −3,103,792 | -$60.28M | EDGAR |
| 2012-02-23 | IDENIX PHARMACEUTICALS INC (IDIX) Delisted | Buy (P) | +169,786 | $582.6K | EDGAR |
| 2011-12-09 | IDENIX PHARMACEUTICALS INC (IDIX) Delisted | Buy (P) | +53,528 | $229.0K | EDGAR |
| 2011-11-22 | IDENIX PHARMACEUTICALS INC (IDIX) Delisted | Buy (P) | +101,060 | $412.8K | EDGAR |
| 2010-11-26 | IDENIX PHARMACEUTICALS INC (IDIX) Delisted | Buy (P) | +34,166 | $93.4K | EDGAR |
| 2010-09-16 | IDENIX PHARMACEUTICALS INC (IDIX) Delisted | Buy (P) | +74,428 | $182.0K | EDGAR |
| 2010-08-23 | IDENIX PHARMACEUTICALS INC (IDIX) Delisted | Buy (P) | +74,428 | $182.0K | EDGAR |
| 2010-02-26 | IDENIX PHARMACEUTICALS INC (IDIX) Delisted | Buy (P) | +3,744 | $9.0K | EDGAR |
| 2009-02-23 | IDENIX PHARMACEUTICALS INC (IDIX) Delisted | Buy (P) | +10,888 | $26.2K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.